查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1994096

导管溶栓装置市场：依产品类型、临床适应症、最终用户及病患年龄组别划分－2026年至2032年全球市场预测

Catheter-Directed Thrombolysis Devices Market by Product Type, Clinical Indication, End User, Patient Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，导管导引溶栓装置市场价值将达到 4.8237 亿美元，到 2026 年将成长至 5.116 亿美元，到 2032 年将达到 6.9582 亿美元，复合年增长率为 5.37%。

主要市场统计数据
基准年 2025 4.8237亿美元
预计年份：2026年 5.116亿美元
预测年份 2032 6.9582亿美元
复合年增长率 (%) 5.37%

为不断发展的临床、营运和商业性趋势制定清晰权威的框架，定义导管引导溶栓治疗的引入和策略重点。

导管导引溶栓治疗作为急性血管闭塞的关键治疗方法，在器械设计、影像整合和手术流程优化等方面的进步推动下不断发展。本执行摘要整合了影响该领域的关键临床、商业性和监管趋势，重点关注器械创新、不断变化的医疗服务格局以及医疗服务提供者和製造商必须应对的营运要求。临床医师越来越倾向于采用标靶治疗，以最大限度地提高溶栓效果，同时最大限度地减少溶栓药物的全身暴露，这进一步凸显了器械性能和输送精准度的重要性。

整合影像、分散式护理路径和策略伙伴关係如何重塑导管引导溶栓的设备设计、临床工作流程和竞争优势。

导管溶栓治疗领域正经历一场变革，这场变革不仅体现在设备升级上，更涵盖了医疗服务模式、数位整合以及以价值为基础的采购。其中一个主要转变是影像、设备控制和手术分析的日益融合。这种更精准的整合使得溶栓药物的输送更加精准，并能即时评估再灌注情况，进而缩短手术时间，减少后续介入。因此，封闭回路型手术支援和资料收集在技术蓝图中的重要性日益凸显，它们将为临床决策和与支付方的互动提供资讯支援。

到 2025 年，关税主导的供应链变化将迫使製造商重组其生产、采购和商业策略，以保护利润率和市场进入。

截至2025年，美国近期一系列关税政策的累积影响已经改变了进入导管导引溶栓治疗市场的医疗设备製造商的供应链计算和策略采购策略。关税提高了某些进口零件和成品的接收成本，促使许多供应商重新评估其采购地点，并加快对近岸外包和国内生产的投资。采购团队目前正在权衡单位成本、前置作业时间容忍度和法规遵循之间的利弊，并越来越多地选择多供应商策略来降低单一供应商的风险。

细分市场的效能要求和部署路径，结合产品架构和医疗保健环境，揭示了它们如何决定临床采用和商业性策略。

对产品和终端用户细分的深入了解揭示了整个导管引导溶栓治疗生态系统中差异化性能的驱动因素和推广应用障碍。根据产品类型，市场动态在输注导管（包括持续输注和脉衝输注）、机械导管亚型（包括抽吸导管、溶栓导管和旋转导管）以及超音波辅助导管（分为增强型超音波和标准型超音波）等类别中存在差异。每类产品都有其独特的临床应用情境和采购考量。输注系统强调可控的稀释剂输送和导管留置特性。机械装置需要在手术速度和栓塞风险之间进行权衡，以减少稀释剂暴露。超音波辅助平台承诺更快地破坏血栓，补偿是系统复杂性增加和训练要求提高。

区域监管复杂性、支付方多样性和不断扩大的产能将如何影响美洲、欧洲、中东和非洲以及亚太地区的差异化打入市场策略？

区域趋势对医疗设备的研发重点、监管策略和商业化部署有显着影响，美洲、欧洲、中东和非洲（EMEA）以及亚太地区各自面临不同的机会和挑战。在美洲，完善的医院网络、成熟的介入治疗专家群体以及微创疗法的快速普及，都为先进溶栓平台的早期应用提供了支持。然而，由于支付方报销政策的差异以及对基于价值的合约日益重视，製造商需要提供强有力的临床和卫生经济学证据，才能在主要医院系统中获得优先地位。

为什么成功的公司要将平台级创新、证据产生和整合服务结合，以在溶栓治疗领域建立可持续的竞争优势？

在导管导引溶栓治疗领域，各公司之间的竞争格局日益呈现临床差异化、系统层级整合和策略伙伴关係三者融合的趋势。领先的研发公司正从提供单一导管产品转向提供包含影像整合、手术分析和服务包的“生态系统策略”，旨在缩短学习曲线并改善治疗效果。这项转变进一步凸显了广泛的临床数据、多中心真实世界数据以及支持强化培训计画的能力的重要性，这些计画有助于降低医疗系统部署风险。

为高阶主管提供可操作的、高优先顺序的行动方案，透过互通性、弹性供应链和有针对性的证据生成，将技术差异化转化为商业性规模。

产业领导者应推动一系列合作倡议，将设备层面的优势转化为永续的商业性成果。首先，应优先考虑互通性的产品架构，以实现与影像和数据系统的快速集成，从而简化流程并促进治疗效果的评估。投资模组化平台可减轻现有客户的升级负担，并透过耗材和服务合约创造持续的商机。其次，应协调临床营运、法规遵循和报销团队，为重点细分市场和地区制定有针对性的证据包。能够证明临床获益和后续经济价值的证据将显着改善与医疗系统的采购谈判。

采用严谨的混合方法研究途径，结合对临床专家的访谈、监管映射和供应链分析，以检验决策者的策略见解。

本分析采用混合研究方法，整合了对关键相关人员的访谈、医疗设备附加檔、同行评审的临床文献，以及对企业资讯披露和临床註册资料的结构化研究途径。重点工作包括与介入性心臟病专家、采购经理和临床营运主管进行访谈，以了解当代决策者和手术趋势。这些定性研究结果与医疗设备适应症、手术通讯协定和已发表的疗效数据的分析结果进行交叉比对，以确保临床结论有证据支持。

整合临床、商业性和营运要求，以明确组织应如何协调投资、证据和供应链，从而在溶栓治疗领域中取得成功。

总之，以导管为基础的溶栓疗法正处于一个转折点，医疗设备创新、医疗服务分散化和价值主导型采购在此交汇，有可能重塑市场格局。产品架构与终端用户需求之间的互动，要求我们制定有针对性的证据和差异化的商业性策略。同时，关税和各地法规差异等外部压力正在重塑供应链和产品优先级，凸显了建立具有韧性的製造体系和灵活筹资策略的必要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：导管导引溶栓装置市场：依产品类型划分

  • 点滴导管
    • 持续输注
    • 脉衝注射
  • 机械导管
    • 吸痰管
    • 理论导管
    • 旋转导管
  • 超音波辅助导管
    • 增强超音波
    • 标准超音波

第九章：导管导引溶栓装置市场：依疾病分类

  • 深层静脉栓塞症
    • 髂股静脉血栓症
    • 股腘窝深层静脉栓塞症
  • 肺动脉栓塞
    • 中度风险肺动脉栓塞
    • 高危险肺动脉栓塞
  • 週边动脉血栓症
    • 急性肢体缺血
  • 透析通路血栓症
  • 静脉支架或移植血栓症

第十章：导管引导式溶栓装置市场：依最终用户划分

  • 医院
  • 门诊手术中心
  • 专科诊所
  • 透析中心

第十一章：依病患年龄组别分類的导管溶栓装置市场

  • 儿童患者
  • 成年患者
  • 老年人

第十二章：导管导引溶栓装置市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：导管引导式溶栓装置市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：导管引导式溶栓装置市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国导管引导式溶栓装置市场

第十六章：中国导管导引溶栓装置市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AngioDynamics, Inc.
  • Asahi Intecc Co., Ltd.
  • Bayer AG
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • BTG Limited
  • Cardinal Health, Inc.
  • Cook Medical LLC
  • Inari Medical, Inc.
  • iVascular SLU
  • Johnson & Johnson Services, Inc.
  • Koninklijke Philips NV
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • Penumbra, Inc.
  • Stryker Corporation
  • Teleflex Incorporated
  • Terumo Corporation
  • Thrombolex, Inc.
Product Code: MRR-1A1A064C03AA

The Catheter-Directed Thrombolysis Devices Market was valued at USD 482.37 million in 2025 and is projected to grow to USD 511.60 million in 2026, with a CAGR of 5.37%, reaching USD 695.82 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 482.37 million
Estimated Year [2026] USD 511.60 million
Forecast Year [2032] USD 695.82 million
CAGR (%) 5.37%

A clear and authoritative framing of the evolving clinical, operational, and commercial dynamics defining catheter-directed thrombolysis adoption and strategic priorities

Catheter-directed thrombolysis continues to evolve as a pivotal intervention for acute vascular occlusions, driven by advances in device design, imaging integration, and procedural workflows. This executive summary synthesizes the critical clinical, commercial, and regulatory dynamics shaping the field, focusing on device innovation, shifting care settings, and the operational requirements that providers and manufacturers must navigate. Clinicians increasingly favor targeted approaches that maximize thrombus resolution while minimizing systemic fibrinolytic exposure, which reinforces the centrality of device-level performance and delivery precision.

Across interventional suites, the interplay between device efficiency and procedural throughput influences adoption curves. Hospitals and specialty clinics demand predictable performance, while ambulatory surgical centers are exploring same-day treatment models that require streamlined protocols and robust safety profiles. In parallel, health economic pressures are prompting procurement teams to scrutinize total cost of care and downstream outcomes, making clinical evidence and real-world performance critical components of adoption strategies.

Regulatory scrutiny and reimbursement considerations are exerting continual influence on product development and commercialization. Developers must balance speed-to-market with rigorous post-market evidence generation to support both clinician confidence and payer engagement. Consequently, strategic alignment between R&D, clinical affairs, and commercial teams becomes a prerequisite for long-term competitiveness. This introduction frames the subsequent analysis, which delves into structural shifts, tariff-driven supply chain implications, segmentation nuances, regional performance vectors, competitive behavior, and practical recommendations for market leaders.

How integrated imaging, decentralized care pathways, and strategic partnerships are reshaping device design, clinical workflows, and competitive moats in catheter-directed thrombolysis

The landscape of catheter-directed thrombolysis is undergoing transformative shifts that extend well beyond discrete device upgrades to encompass care delivery models, digital integration, and value-based procurement. One major change is the growing convergence of imaging, device control, and procedural analytics. Enhanced integration permits precise targeting of thrombolytic delivery and real-time assessment of reperfusion, which in turn supports shorter procedures and potentially fewer follow-up interventions. As a result, technology roadmaps increasingly prioritize closed-loop procedural support and data capture to inform both clinical decision-making and payer conversations.

Another critical trend is the decentralization of vascular care. Ambulatory settings and specialty clinics are expanding their procedural portfolios, demanding devices that are intuitive, have reduced accessory requirements, and can be deployed with smaller care teams. This operational shift necessitates new training paradigms and redefined value propositions for manufacturers, who must demonstrate ease of use alongside clinical efficacy. Meanwhile, device developers are accelerating modularization and platform strategies so that incremental innovations can be introduced without full-system replacements, thereby preserving installed-base relationships and smoothing upgrade cycles.

Finally, cross-sector partnerships are reshaping competitive dynamics. Collaborations between device OEMs, imaging companies, and digital health firms are enabling bundled solutions that emphasize outcome tracking and procedural optimization. These alliances are creating higher barriers to entry for single-product suppliers and rewarding firms that can offer integrated clinical workflows. Taken together, these transformative shifts require stakeholders to prioritize interoperability, training, and evidence generation to secure long-term relevance.

How tariff-driven supply chain shifts through 2025 are forcing manufacturers to reconfigure production, sourcing, and commercial strategies to protect margin and access

The cumulative impact of recent tariff policies in the United States through 2025 has altered supply chain calculus and strategic sourcing for device manufacturers serving the catheter-directed thrombolysis market. Tariffs have increased the landed cost of certain imported components and finished goods, prompting many suppliers to reassess their sourcing footprints and to accelerate nearshoring or domestic manufacturing investments. Procurement teams now weigh the trade-offs between unit cost, lead-time resilience, and regulatory compliance, often selecting multi-sourcing strategies to mitigate single-origin risk.

In response to tariff-driven cost pressures, manufacturers have pursued process and product-level optimizations to preserve margin while maintaining clinical performance. These adjustments include greater use of local contract manufacturing organizations for final assembly, reengineering of packaging to reduce freight volumetrics, and negotiation of longer-term supplier agreements to stabilize input pricing. Concurrently, some companies have adopted hedging strategies and pricing clauses that pass a portion of increased input costs through to purchasers, while others have absorbed costs temporarily to maintain competitive positioning.

From a market access perspective, tariff effects have influenced device lifecycle decisions, such as prioritizing higher-margin product lines for domestic production and postponing lower-margin variants that are more exposed to import costs. In addition, tariff uncertainty has elevated the importance of scenario planning within commercial strategies, with firms building flexible go-to-market playbooks that can adapt to sudden cost shifts. Ultimately, the tariff environment through 2025 has reinforced the strategic value of supply chain transparency, nimble manufacturing, and close collaboration across procurement, regulatory, and commercial functions to protect access and sustain innovation.

Segment-specific performance imperatives and adoption pathways reveal how product architecture and care settings jointly determine clinical uptake and commercial playbooks

A granular understanding of product and end-user segmentation reveals differentiated performance drivers and adoption barriers across the catheter-directed thrombolysis ecosystem. Based on Product Type, market dynamics diverge between Infusion Catheter variants such as Continuous Infusion and Pulsatile Infusion, Mechanical Catheter subtypes including Aspiration Catheter, Rheolytic Catheter, and Rotational Catheter, and Ultrasound-Assisted Catheter categories split into Enhanced Ultrasound and Standard Ultrasound. Each product class presents unique clinical use-cases and procurement considerations: infusion-based systems emphasize controlled lytic delivery and catheter dwell characteristics; mechanical devices trade off procedural speed and embolic risk for reduced lytic exposure; and ultrasound-enabled platforms promise faster thrombus disruption at the cost of additional system complexity and training demands.

Based on End User, adoption pathways differ across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics, with each setting imposing distinct requirements on device usability, inventory management, and ancillary services. Hospitals typically demand devices that fit into complex care pathways, offering comprehensive training support, service contracts, and immediate technical escalation. Specialty clinics value targeted performance attributes and streamlined reimbursement support, while ambulatory surgical centers prioritize devices that minimize procedure time, reduce post-procedural monitoring, and support same-day discharge. These differences influence product design priorities and commercial tactics, such as bundled offering development, clinical training programs, and flexible financing structures.

Transitioning from segmentation to execution, manufacturers should align clinical evidence generation and customer engagement with the unique requirements of each product subtype and end-user setting. By mapping clinical workflows to device capabilities and reimbursement pathways, organizations can craft differentiated value narratives and targeted adoption pilots that demonstrably address provider pain points while minimizing operational friction.

How regional regulatory complexity, payer heterogeneity, and capacity expansion shape differentiated market access strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics exert a profound influence on device development priorities, regulatory strategy, and commercial deployment, with the Americas, Europe, Middle East & Africa, and Asia-Pacific each presenting distinct vectors of opportunity and constraint. In the Americas, strong hospital networks, established interventional specialist communities, and relatively rapid adoption of minimally invasive therapies support early uptake of advanced thrombolysis platforms. However, heterogeneity in payer reimbursement policies and the increasing emphasis on value-based contracting require manufacturers to present robust clinical and health economic evidence to secure preferred positioning with large hospital systems.

Europe, Middle East & Africa encompasses a wide spectrum of regulatory regimes and procurement approaches, where centralized reimbursement decisions in some jurisdictions coexist with hospital-level purchasing practices in others. This regional complexity necessitates adaptive market access strategies, such as modular clinical programs that can be calibrated to local evidence requirements and commercial partnerships that extend reimbursement support and clinician training. In contrast, Asia-Pacific is characterized by rapid capacity expansion, an expanding interventionalist workforce, and intense price sensitivity in several markets. Manufacturers seeking traction in APAC often combine tiered pricing models with local training initiatives and selective manufacturing partnerships to meet cost and regulatory demands.

Across all regions, cross-border coordination of clinical evidence, post-market surveillance, and supply chain resilience is critical. Firms that can harmonize global regulatory submissions, while tailoring real-world evidence collection and pricing approaches to regional specifics, are better positioned to scale adoption efficiently and to manage the operational complexity inherent in multi-regional rollouts.

Why successful companies combine platform-level innovation, evidence generation, and integrated services to build durable competitive advantage in thrombolysis therapies

Competitive dynamics among firms active in catheter-directed thrombolysis are increasingly defined by a blend of clinical differentiation, systems-level integration, and strategic partnerships. Leading developers have shifted from offering singular catheter products to providing ecosystem plays that include imaging integration, procedural analytics, and service packages designed to shorten learning curves and improve outcomes. This movement elevates the importance of breadth in clinical data, multi-center real-world evidence, and the capability to support intensive training programs that de-risk adoption for health systems.

Acquisitions and licensing deals are commonplace as companies seek to augment technical portfolios with complementary technologies such as ultrasound energy delivery, advanced infusion control, or thrombectomy modalities. Firms that have invested early in platform architectures gain an advantage because modular upgrades can be introduced with less disruption to existing customers, fostering stickiness and recurring revenue through consumables and service agreements. At the same time, agile smaller companies often drive innovation in niche product features and can influence clinical practice when their solutions demonstrably reduce procedure time or complication rates.

From a go-to-market perspective, successful companies combine clinical and economic narratives. They articulate not only improvements in vessel patency and procedural efficiency but also measurable reductions in length of stay, readmission risk, and adverse event rates. Those that collaborate closely with key opinion leaders to publish outcomes and to design pragmatic training curricula tend to accelerate clinician trust and adoption. To preserve competitive advantage, leading firms are investing in post-market surveillance systems and outcome registries that continually reinforce product value and inform iterative design enhancements.

Practical and prioritized actions for executives to convert technical differentiation into commercial scale through interoperability, resilient supply chains, and targeted evidence generation

Industry leaders should pursue a set of coordinated actions that translate device-level advantages into sustainable commercial outcomes. First, prioritize interoperable product architectures that enable rapid integration with imaging and data systems, thereby creating procedural efficiencies and facilitating outcome measurement. Investing in modular platforms reduces upgrade friction for existing customers and creates recurring revenue opportunities through consumables and service contracts. Second, align clinical affairs, regulatory, and reimbursement teams to develop targeted evidence packages for prioritized segments and regions; evidence that demonstrates both clinical benefit and downstream economic value will materially improve procurement conversations with health systems.

Third, strengthen supply chain resilience through dual sourcing, regional manufacturing partnerships, and transparent inventory analytics to mitigate tariff and logistics risks. This reduces vulnerability to input-cost shocks and supports reliable customer delivery timelines. Fourth, deploy differentiated commercial models that reflect end-user needs-hospitals require comprehensive training and service support, specialty clinics value streamlined deployment and cost predictability, and ambulatory surgical centers seek devices that enable same-day pathways. Tailored pricing, financing, and training packages will accelerate adoption across these settings.

Finally, commit to collaborative partnerships with clinical centers for real-world evidence generation and procedural optimization. These collaborations should target clinical outcome registries and pragmatic trials that inform continuous product improvements and strengthen payer engagement. By executing on these priorities with discipline, industry leaders can convert technological innovation into measurable improvements in patient outcomes and durable market positions.

A rigorous mixed-methods research approach combining clinical expert interviews, regulatory mapping, and supply chain analysis to validate strategic insights for decision-makers

This analysis is grounded in a mixed-methods research approach that synthesizes primary stakeholder interviews, device labeling and regulatory documentation, peer-reviewed clinical literature, and a structured review of company disclosures and clinical registries. Primary engagement included interviews with interventional specialists, procurement leaders, and clinical affairs executives to capture contemporary decision drivers and procedural trends. These qualitative insights were triangulated with an analysis of device indications, procedural protocols, and published outcome data to ensure clinical assertions are supported by evidence.

Supplementing qualitative inputs, the methodology incorporated a structured assessment of supply chain footprints, tariff exposures, and manufacturing options based on publicly available trade and customs data. Regional regulatory frameworks were mapped against device classification and pre-market pathways to identify typical requirements and potential accelerators for market entry. Additionally, competitive behavior was examined through disclosures, patent filings, and partnership announcements to identify strategic patterns such as platform expansion, vertical integration, and service-oriented monetization.

Throughout the research process, rigorous validation practices were applied. Key findings and interpretations were subjected to expert review and iterative refinement with clinical and commercial advisors. Where appropriate, sensitivity to regional heterogeneity and clinical practice variation was maintained to avoid overgeneralization. This methodological rigor supports both the credibility of the insights presented and their applicability to practical strategy development.

A synthesis of clinical, commercial, and operational imperatives that clarifies how organizations should align investment, evidence, and supply chains to win in thrombolysis

In conclusion, catheter-directed thrombolysis is at an inflection point where device innovation, care-setting decentralization, and value-driven procurement intersect to redefine market trajectories. The interplay between product architecture and end-user requirements necessitates focused evidence generation and differentiated commercial approaches. Meanwhile, external pressures such as tariffs and regional regulatory diversity are reshaping supply chains and product prioritization, underscoring the need for resilient manufacturing and flexible sourcing strategies.

Manufacturers that invest in interoperable platforms, build compelling health economic narratives, and pursue pragmatic partnerships with clinical centers will be best positioned to capture long-term value. Likewise, commercial leaders must tailor propositions to the distinct operational realities of hospitals, specialty clinics, and ambulatory surgical centers, while maintaining the agility to adapt to regional nuances. Ultimately, success will rest on the ability to translate technical improvements into demonstrable clinical outcomes and measurable reductions in total cost of care, thereby answering the practical questions that payers and providers pose during procurement.

This executive summary is intended to inform strategic planning, guide prioritization of R&D and market access investments, and support alignment across clinical, regulatory, and commercial functions so that organizations can confidently navigate the evolving landscape and accelerate adoption of best-in-class thrombolysis solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Catheter-Directed Thrombolysis Devices Market, by Product Type

  • 8.1. Infusion Catheter
    • 8.1.1. Continuous Infusion
    • 8.1.2. Pulsatile Infusion
  • 8.2. Mechanical Catheter
    • 8.2.1. Aspiration Catheter
    • 8.2.2. Rheolytic Catheter
    • 8.2.3. Rotational Catheter
  • 8.3. Ultrasound-Assisted Catheter
    • 8.3.1. Enhanced Ultrasound
    • 8.3.2. Standard Ultrasound

9. Catheter-Directed Thrombolysis Devices Market, by Clinical Indication

  • 9.1. Deep Vein Thrombosis
    • 9.1.1. Iliofemoral Deep Vein Thrombosis
    • 9.1.2. Femoro-Popliteal Deep Vein Thrombosis
  • 9.2. Pulmonary Embolism
    • 9.2.1. Intermediate-Risk Pulmonary Embolism
    • 9.2.2. High-Risk Pulmonary Embolism
  • 9.3. Peripheral Arterial Thrombosis
    • 9.3.1. Acute Limb Ischemia
  • 9.4. Dialysis Access Thrombosis
  • 9.5. Venous Stent Or Graft Thrombosis

10. Catheter-Directed Thrombolysis Devices Market, by End User

  • 10.1. Hospitals
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Specialty Clinics
  • 10.4. Dialysis Centers

11. Catheter-Directed Thrombolysis Devices Market, by Patient Age Group

  • 11.1. Pediatric Patients
  • 11.2. Adult Patients
  • 11.3. Geriatric Patients

12. Catheter-Directed Thrombolysis Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Catheter-Directed Thrombolysis Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Catheter-Directed Thrombolysis Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Catheter-Directed Thrombolysis Devices Market

16. China Catheter-Directed Thrombolysis Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. AngioDynamics, Inc.
  • 17.7. Asahi Intecc Co., Ltd.
  • 17.8. Bayer AG
  • 17.9. Becton, Dickinson and Company
  • 17.10. Boston Scientific Corporation
  • 17.11. BTG Limited
  • 17.12. Cardinal Health, Inc.
  • 17.13. Cook Medical LLC
  • 17.14. Inari Medical, Inc.
  • 17.15. iVascular S.L.U.
  • 17.16. Johnson & Johnson Services, Inc.
  • 17.17. Koninklijke Philips N.V.
  • 17.18. Medtronic plc
  • 17.19. Merit Medical Systems, Inc.
  • 17.20. Penumbra, Inc.
  • 17.21. Stryker Corporation
  • 17.22. Teleflex Incorporated
  • 17.23. Terumo Corporation
  • 17.24. Thrombolex, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CONTINUOUS INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CONTINUOUS INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CONTINUOUS INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULSATILE INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULSATILE INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULSATILE INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ASPIRATION CATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ASPIRATION CATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ASPIRATION CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY RHEOLYTIC CATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY RHEOLYTIC CATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY RHEOLYTIC CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ROTATIONAL CATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ROTATIONAL CATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ROTATIONAL CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ENHANCED ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ENHANCED ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ENHANCED ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY STANDARD ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY STANDARD ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY STANDARD ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ILIOFEMORAL DEEP VEIN THROMBOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ILIOFEMORAL DEEP VEIN THROMBOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ILIOFEMORAL DEEP VEIN THROMBOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY FEMORO-POPLITEAL DEEP VEIN THROMBOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY FEMORO-POPLITEAL DEEP VEIN THROMBOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY FEMORO-POPLITEAL DEEP VEIN THROMBOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INTERMEDIATE-RISK PULMONARY EMBOLISM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INTERMEDIATE-RISK PULMONARY EMBOLISM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INTERMEDIATE-RISK PULMONARY EMBOLISM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY HIGH-RISK PULMONARY EMBOLISM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY HIGH-RISK PULMONARY EMBOLISM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY HIGH-RISK PULMONARY EMBOLISM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ACUTE LIMB ISCHEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ACUTE LIMB ISCHEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ACUTE LIMB ISCHEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DIALYSIS ACCESS THROMBOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DIALYSIS ACCESS THROMBOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DIALYSIS ACCESS THROMBOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY VENOUS STENT OR GRAFT THROMBOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY VENOUS STENT OR GRAFT THROMBOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY VENOUS STENT OR GRAFT THROMBOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DIALYSIS CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DIALYSIS CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DIALYSIS CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY GERIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY GERIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 197. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 198. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 199. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 200. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 201. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 202. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 203. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. GCC CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 230. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 231. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 232. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 233. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 234. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 235. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 236. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. G7 CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 241. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 242. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 243. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 244. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 245. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 246. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 247. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. NATO CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PULMONARY EMBOLISM, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY INFUSION CATHETER, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY MECHANICAL CATHETER, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED CATHETER, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA CATHETER-DIRECTED THROMBOLYSIS DEVICES MARKET SIZE, BY DEEP VEIN THROM